

### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

earning royanties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Drewes 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Abjørn Mohr	2. Surname (Last Name) Drewes	3. Date 07-August-2019
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Torsten W Licht
5. Manuscript Title Opioider til kroniske non-maligne smert	er: Behov for nuancering	og individuel patientbehandling
6. Manuscript Identifying Number (if you know UFL-06-19-0339	ow it)	_
Section 2		
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
•	rmation below. If you hav	ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	or-Financial other? Comments
Grünenthal		
Section 3. Relevant financial a	activities outside the	submitted work.
of compensation) with entities as descril	bed in the instructions. Use port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
ŕ		
Section 4. Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether planr	ned, pending or issued, bi	roadly relevant to the work? Yes V No

Drewes 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	inuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. In als may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen, men ikke for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Drewes 3



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Bredahl 1



Section 1. Identifying Inform	ation			
1. Given Name (First Name) Claus	2. Surname (Last Name) Bredahl		3. Date 13-July-2019	
4. Are you the corresponding author?	Yes✓ No	Corresponding Author's Name Torsten Licht		
5. Manuscript Title Opioider til kroniske non-maligne smert	er: Behov for nuancering	og individuel patient	tbehandling	
6. Manuscript Identifying Number (if you kn UFL-06-19-0339	ow it)	_		
Section 2. The Work Under Co	nsideration for Public	cation		
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not limited to grants, da	ita monitoring board, s	tudy design, manuscript preparation,	
If yes, please fill out the appropriate info Excess rows can be removed by pressing	•	e more than one ent	ity press the "ADD" button to add a	row.
Name of Institution/Company	Grant? Personal No	n-Financial Other?	Comments	
Grünenthal.			Deltagelse i Advisory Board møde, Februar 2019, vedr. opioider. Se General Disclosure Statement forneden.	
Section 3. Relevant financial a	activities outside the s	submitted work.		
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	oed in the instructions. Use ort relationships that wer	se one line for each e	ntity; add as many lines as you need	d by
Section 4. Intellectual Proper	ty Patents & Copyri	ghts		
Do you have any patents, whether planr	ned, pending or issued, br	oadly relevant to the	e work? Yes 🗸 No	

Bredahl 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	inuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. In als may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen men <u>ikke</u> for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bredahl 3



### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Lars	2. Surname (Last Name) Arendt-Nielsen		3. Date 15-July-2019
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Autho Torsten Licht	r's Name
5. Manuscript Title Opioider til kroniske non-maligne smert	er: Behov for nuancering	og individuel patientk	pehandling
6. Manuscript Identifying Number (if you kn UFL-06-19-0339	ow it)	_	
Coation 2			
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing	but not limited to grants, da st?	ta monitoring board, stu	ıdy design, manuscript preparation,
Name of Institution/Company	Grant? Personal Nor	n-Financial Other?	Comments
Grünenthal	Tees 5		
Continu 2			
Section 3. Relevant financial a	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repare there any relevant conflicts of interesting the please fill out the appropriate info	bed in the instructions. Us ort relationships that wer st?	e one line for each en	tity; add as many lines as you need by
Name of Entity	Grant	n-Financial other?	Comments
Se venligst sektion 6 med liste over modtagne honorarer og forskningsbevillinger.	<b>V</b>		



Section 4. Intellectual Property - Patonts & Conscients
Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
Jeg er p.t. Præsident for IASP: International Association for the Study of Pain
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen men <u>ikke</u> for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.

Modtaget foredragshonorar fra: Allergan, Grünenthal, Ono, Abbott, Boehringer-Ingelheim, Pfizer, Bristol-Myers Squibb, Daiichi Sankyo, Shionogi, Ironwood Pharma, Eli Lilly, Mundipharma, Purdue, Pierre Fabre, Sanofi-Aventis, Vertex Pharmaceuticals, UCB.

Modtaget forskningsbevillinger fra: Shionogi, Daiichi Sankyo, Grünenthal, Merck.



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Christrup 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Lona Louring	2. Surname (Last Name) Christrup	3. Date 14-July-2019
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Lars Arendt-Nielsen
5. Manuscript Title Opioider til kroniske non-maligne smert	ter: Behov for nuancering	og individuel patientbehandling
6. Manuscript Identifying Number (if you kn UFL-06-19-0339	ow it)	_
Section 2. The Work Under Co	onsideration for Publi	cation
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere		
If yes, please fill out the appropriate info Excess rows can be removed by pressing	•	ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	on-Financial Support? Comments
Grünenthal		
Section 3. Relevant financial a	activities outside the	submitted work.
of compensation) with entities as descri	bed in the instructions. Uport relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re <b>present during the 36 months prior to publication</b> .
Continue		
Section 4. Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether plant	ned, pending or issued, b	roadly relevant to the work? Yes V No

Christrup 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen, men ikke for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.
Dr. Christrup reports personal fees from Grünenthal, during the conduct of the study.
Evaluation and Feedback

Christrup 3

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Bache 1



Section 1. Identifying Inform	ation				
1. Given Name (First Name) Nina	2. Surname (Last Name) Bache		3. Date 15-July-2019		
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Torsten Licht			
5. Manuscript Title Opioider til kroniske non-maligne smer	ter: Behov for nuancering	og individuel patient	tbehandling		
6. Manuscript Identifying Number (if you kn UFL-06-19-0339	ow it)				
Section 2. The Work Under Co	onsideration for Public	cation			
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info	but not limited to grants, datest? Yes No ormation below. If you have	ata monitoring board, s	nent, commercial, private foundation, etc.) for tudy design, manuscript preparation, etc.) sity press the "ADD" button to add a row.		
Excess rows can be removed by pressing	g the "X" button.				
Name of Institution/Company	Grant	n-Financial other?	Comments		
Grûnenthal			Fået honorar for at deltage i et advisery board, der udgjorde datagrundlaget for artiklen.		
Section 3. Relevant financial	activities outside the s	submitted work.			
Place a check in the appropriate boxes i of compensation) with entities as descriclicking the "Add +" box. You should rep	bed in the instructions. Use port relationships that wer	se one line for each e	ntity; add as many lines as you need by		
Are there any relevant conflicts of intere	est? Yes V No				
Section 4. Intellectual Proper	ty Patents & Copyrig	whee			
intellectual Proper	ty ratents & copyrig	51165			
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the	e work? ☐ Yes   ✓ No		

Bache 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen, men ikke for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.

Har ikke fået et honorar for medforfatterskab.

**Disclosure Statement** 

Section 6.

Har modtaget honorar fra firmet Grûnenthal for deltagelse i advisory board februar 2019, hvor behandling med opioider blev diskuteret. Data fra mødet, danner grundlag for artiklen. Grünenthal har bidraget med at betale udgifter til medical writer.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bache 3



### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Licht



Section 1. Identifying Inform	ation				
1. Given Name (First Name) Torsten Wentzer	2. Surname (Last Name) Licht	)		3. Date 05-August-2019	
4. Are you the corresponding author?	<b>√</b> Yes  No				
5. Manuscript Title Opioider til kroniske non-maligne smert	er: Behov for nuancerir	ng og individuel	patientbeha	ındling	
6. Manuscript Identifying Number (if you kn UFL-06-19-0339	ow it)				
Section 2					
Section 2. The Work Under Co	onsideration for Pub	olication			
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing	but not limited to grants, st?  Yes  No rmation below. If you h	data monitoring	board, study d	lesign, manuscript preparation,	
Name of Institution/Company	Grant? Personal N	Ion-Financial Support	Other? Co	omments	
Grünenthal				ltaget honorar i forbindelse med agelse i Advisory Board i februar D.	
Section 3. Relevant financial:	activities outside th	e submitted v	ork .		
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	n the table to indicate we bed in the instructions. Fort relationships that w	whether you hav Use one line for vere <b>present d</b> u	re financial re each entity;	add as many lines as you need	
Section 4. Intellectual Proper	ty Patents & Copy	riahts			
Do you have any patents, whether plann			t to the work	☐ Yes ✓ No</td <td></td>	

Licht 2



**Disclosure Statement** 

## **ICMJE Form for Disclosure of Potential Conflicts of Interest**

Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	ving relationships/conditions/circumstances are present (explain below): cionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. nals may ask authors to disclose further information about reported relationships.
Section 6.	Disalagura Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen, men ikke for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Licht 3



### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Gregersen 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Thomas	2. Surname (Last Name) Gregersen	3. Date 07-August-2019
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Torsten Licht
5. Manuscript Title Opioider til kroniske non-maligne smert	er: Behov for nuancering	og individuel patientbehandling
6. Manuscript Identifying Number (if you kn UFL-06-19-0339	ow it)	_
Section 2. The Work Under Co	onsideration for Publi	cation
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere		I A DON'T
Excess rows can be removed by pressing		ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	on-Financial Other? Comments
Grünenthal		
Section 3. Relevant financial a	activities outside the	submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V		
Section 4. Intellectual Proper		
Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether plans	ned, pending or issued, bi	roadly relevant to the work? Yes No

Gregersen 2



**Disclosure Statement** 

## **ICMJE Form for Disclosure of Potential Conflicts of Interest**

Section 5.	Relationships not covered above	
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?		
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.		
Section 6.	Diselective Statement	

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Statusartiklen er blevet til ved at alle forfattere deltog i et Advisory Board møde i Februar 2019, afholdt af Grünenthal, hvor behandling med opioider blev diskuteret. Diskussionerne på dette Advisory Board og referatet herfra er datagrundlaget for artiklen. Deltagerne modtog honorering for selve Advisory Board deltagelsen, men ikke for og under tilblivelsen af manuskriptet. Medical Writers Christina Johnson og Michael Bachmann (Copentown Healthcare Consultants) supporterede denne process. Deres honorar blev betalt af Grünenthal.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Gregersen 3